Skip to main content

ChEMBL funding 2014-2019.


We have recently heard that our funding application for continuation of the ChEMBL database has been successful, and going forward the resource will be funded by The Wellcome Trust and core-funding from EMBL. Below is the text from the lay description of the application. First though, we must thank you, ChEMBL users, for your support and feedback to all that we do. There is a lot of exciting future data and technology to come, and we'll post more details about what we plan to do in future blog posts. As always, we are always happy to receive visitors for tea and cake!

Drug Discovery is costly, slow and complex, and despite much fundamental scientific progress, the translation of this into new safer medicines has been slower than anticipated. One of the key steps in drug discovery is the identification of specific drug-like bioactive compounds that modulate a gene believed to be causal in the treatment of a disease. Most new drugs are themselves chemically similar to old drugs, but target new proteins, or with improved properties and distribution within the body. Understanding the activity of previous drug-like compounds is therefore key to the discovery of new drugs. However, much of the data in drug discovery is locked away in patents, publications and within companies. Our work, the ChEMBL database, builds a large database of relationships between drugs, other bioactive compounds, genes and biological function to provide a unique resource linking Genomics, Biology and Chemistry. The data we provide is all completely Open and has become an important source of data for academic, rare and neglected disease, small companies and large Pharma therapeutic discovery.

In this current application we will develop:

1) Greater coverage of bioactivity space - to deepen and formalise the data contained in ChEMBL via further curation.
2) Enhanced indexing with ontologies - to provide more structured data and ease integration with other resources.
3) Patent coverage - extend chemical-structure/target data to include the patent literature.
4) Address variation data – to include annotation of resistance and natural population variation data.
5) Technology enhancements - including RDF forms of ChEMBL and development of an API to ease data entry and curation tasks.
6) Expanded user community of ChEMBL - develop interfaces with new beneficiaries in clinical and biotechnology communities.

Comments

Chris said…
Great news!
Janna Hastings said…
Congratulations ChEMBL team! Great news.

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

ChEMBL 26 Released

We are pleased to announce the release of ChEMBL_26 This version of the database, prepared on 10/01/2020 contains: 2,425,876 compound records 1,950,765 compounds (of which 1,940,733 have mol files) 15,996,368 activities 1,221,311 assays 13,377 targets 76,076 documents You can query the ChEMBL 26 data online via the ChEMBL Interface and you can also download the data from the ChEMBL FTP site . Please see ChEMBL_26 release notes for full details of all changes in this release. Changes since the last release: * Deposited Data Sets: CO-ADD antimicrobial screening data: Two new data sets have been included from the Community for Open Access Drug Discovery (CO-ADD). These data sets are screening of the NIH NCI Natural Product Set III in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296183, DOI = 10.6019/CHEMBL4296183) and screening of the NIH NCI Diversity Set V in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296182, DOI = 10.601